MRX-2843
MRX-2843 (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively[1].
Product Specifications
CAS Number
1429882-07-4
Product Name Alternative
UNC2371
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
FLT3
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MRX-2843.html
Purity
99.56
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O[C@H]1CC[C@H](N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C5=CN=C(NCCC6CC6)N=C52)CC1
Molecular Formula
C29H40N6O
Molecular Weight
488.67
Precautions
H315, H319, H335
References & Citations
[1]Minson KA, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1 (3) :e85630.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC742059-100 1x 100 µL
TNFS15 / VEGI (Vascular Endothelial Growth Inhibitor) (rVEGI/1283), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
